Novavax, Inc.
NVAX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $682,162 | $556,382 | $1,598,951 | $197,581 |
| % Growth | 22.6% | -65.2% | 709.3% | – |
| Cost of Goods Sold | $202,739 | $343,768 | $902,639 | $0 |
| Gross Profit | $479,423 | $212,614 | $696,312 | $197,581 |
| % Margin | 70.3% | 38.2% | 43.5% | 100% |
| R&D Expenses | $391,169 | $737,502 | $1,235,278 | $2,534,508 |
| G&A Expenses | $0 | $0 | $488,691 | $298,358 |
| SG&A Expenses | $337,185 | $468,946 | $488,691 | $298,358 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$427,323 | -$382,921 | -$948,709 |
| Operating Expenses | $728,354 | $779,125 | $1,341,048 | $1,884,157 |
| Operating Income | -$248,931 | -$566,511 | -$644,736 | -$1,686,576 |
| % Margin | -36.5% | -101.8% | -40.3% | -853.6% |
| Other Income/Exp. Net | $72,316 | $23,480 | -$8,911 | -$27,960 |
| Pre-Tax Income | -$176,615 | -$543,031 | -$653,647 | -$1,714,536 |
| Tax Expense | $10,884 | $2,031 | $4,292 | $29,215 |
| Net Income | -$187,499 | -$545,062 | -$657,939 | -$1,743,751 |
| % Margin | -27.5% | -98% | -41.1% | -882.5% |
| EPS | -1.23 | -5.41 | -8.42 | -23.44 |
| % Growth | 77.3% | 35.7% | 64.1% | – |
| EPS Diluted | -1.23 | -5.41 | -8.42 | -23.44 |
| Weighted Avg Shares Out | 152,190 | 100,768 | 78,183 | 74,400 |
| Weighted Avg Shares Out Dil | 152,190 | 100,768 | 78,183 | 74,400 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $20,075 | $14,416 | $19,880 | $21,127 |
| Depreciation & Amortization | $48,496 | $41,225 | $29,054 | $12,661 |
| EBITDA | -$108,044 | -$487,390 | -$604,713 | -$1,680,748 |
| % Margin | -15.8% | -87.6% | -37.8% | -850.7% |